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Abstract. Peroxiredoxin (Prx) I is an antioxidant protein expressed in proliferating cells. 
We investigated Prx I as marker for tongue cancer status by correlating clinical features 
with Prx I expression. Samples from 132 patients with squamous cell carcinoma in the 
tongue were examined by immunohistochemistry with anti-Prx I antibodies. 
Correlations between Prx I expression and the clinical features of tumors were 
statistically determined using univariate and multivariate analyses. Univariate analysis 
showed Prx I was significantly associated with local recurrence (P = 0.033). By multiple 
logistic regression analysis, Prx I expression was associated with local recurrence (odds 
ratio: 2.84; 95% confidence interval: 1.09-7.43; P = 0.034) and lymph node recurrence 
(odds ratio: 2.86; 95% confidence interval: 1.02-8.01; P = 0.046). Our results suggested 
that Prx I expression indicates tumors with a high potential for recurrence. Prx I may be 
used clinically to guide treatment for squamous cell carcinoma of the tongue. 
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Introduction 
The peroxiredoxin (Prx) antioxidant protein family is found in a wide variety of 
species and plays important roles in protecting cells against oxidants and in regulating 
signaling by hydrogen peroxide.  Its structure was recently reported and analyzed with 
respect to these dual roles24. At least six Prx enzymes are present in mammals (Prx 
I-VI)15. These Prx isoforms are found in the cytosol, mitochondria, peroxisomes, and 
plasma, all of which are potential sites of reactive oxygen species (ROS) production3, 5, 8, 
9, 12, 17.  
     Pag (human Prx I) was originally isolated by differential screening of cDNA 
libraries made from untransformed and ras-transformed human mammary epithelial 
cells. Because these cells cease proliferating during the commitment phase of 
differentiation, the higher levels of pag gene expression were correlated with cell 
proliferation13. Furthermore, some reports show an association between Prx I and the 
protooncogene product c-Abl, Myc, and cell cycle factor cdc21, 23. Taken together, these 
findings indicate that Prx I is associated with cell proliferation and tumor growth.  
There are many reports of markers for proliferation, e.g., argynophilic nucleolar 
organizer regions (AgNORs), Ki67, and proliferating cell nuclear antigen (PCNA), that 
have been suggested to have clinical applications7, 21, 22. Although there are many 
reports on proliferation markers in the head and neck region, few focus on Prx I. We 
previously investigated oral squamous cell carcinoma and reported the potential 
usefulness of Prx I as a marker for clinicopathological features compared with PCNA26. 
However these results were not sufficient for clinical applications, because the samples 
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originated from various oral regions, a rather small number of cases was analyzed, and 
only univariate analysis was used. In this study, we determined Prx I expression in 132 
cases of tongue squamous cell carcinoma (SCC) by immunohistochemistry and 
examined correlations with the clinical status of the tongue cancer to investigate the 
usefulness of Prx I as a clinical indicator for tumor characteristics.  
 
Patients and methods  
 
Patients 
Tumor specimens were obtained by punch biopsies of the tongue from 132 patients 
who consulted the Division of Head and Neck Surgery, Chiba Cancer Center Hospital, 
from 1970 to 1995. The clinical features of these patients are summarized in Table 1. 
The tumors were staged according to the International Union Against Cancer (UICC) 
scheme19. The characteristics of the tumors are also shown in Table 1 for each case. No 
treatments for the malignant tumors were performed prior to biopsy. The tumor 
macroscopic morphology was used to classify the tumors into 4 groups: superficial, 
exophytic, endophytic, and combination type, as described previously18. Four patients 
were treated with surgical excision alone, 65 received surgical excision and radiotherapy, 
and the remaining 63 patients received radiation therapy alone. Of the 128 patients who 
received radiotherapy treatment, 25 were treated with linac radiation alone (8-70 Gy), 
35 received interstitial radiation alone (28-70 Gy), 2 received electron beam therapy 
alone (42-50 Gy), and 66 received a combination of these radiation therapies (48.6-83 
 YANAGAWA-6 
Gy). Local recurrence was defined as tumor recurrence in the primary region after 
primary treatment. Lymph node recurrence was defined as lymph node metastasis after 
primary treatment, including no treatment of the regional cervical lymph node. Lymph 
node metastasis was confirmed by histologically. 
 
Methods 
Immunostaining was performed using the horseradish peroxidase-labeled 
streptavidin and biotin technique. The samples were obtained by punch biopsy, fixed in 
10% formalin neutral buffered solution, and embedded in paraffin. The slides were 
incubated for 1 hour at room temperature with an anti-Prx I rabbit polyclonal antibody 
produced by our group4, diluted 1: 500 v/v in PBS. The slides were then incubated with 
biotinylated goat anti-rabbit IgG antibody, followed by horseradish 
peroxidase-conjugated streptavidin, and visualized with 3,3'-diaminobenzidine. One 
pathologist, who was not informed of the patients' clinical status, examined the 
immunostained slides. The Prx I immunostaining was categorized as negative (Fig. 1A) 
or positive (Fig. 1B), with total absence of Prx I being defined as negative staining. 
Control staining was performed with non-immune rabbit or mouse serum. As in our 
previous report, diseased thyroid tissues were immunoblotted as positive or negative 
controls for Prx I staining26. To confirm that the disparity in staining among sections 
was not due to the condition of samples, we divided the samples into old ones (collected 
before August 1986) and new ones (collected later than August 1986) and analyzed the 
groups statistically by the chi-square test. The positive-to-negative ratio in the old 
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samples was 26/40 and in the new samples was 27/39. Therefore, the disparity in 
staining was not significantly influenced by the time since fixation or the storage 
conditions (P = 0.86).  
For univariate analysis, we used the chi-square test. For multivariate analysis, 
multiple logistic regression analysis was used. The analyses were performed using the 
StatView 5.0 statistical software package (SAS Institute Inc., Cary, NC, USA). 
 
Results 
Univariate analysis of Prx I expression and recurrence 
Prx I expression was observed in the epithelium of the SCC in 79% of the 
specimens examined. To simplify the analysis for the correlation of Prx I expression 
with clinical features, the T-categories were divided into T1 + T2 and T3 + T4 groups, 
and the N-categories as lymph node metastasis negative (N0) and lymph node 
metastasis positive (N1+2) groups. The clinical stages were subclassified into stage I + 
II and stage III+IV. The differentiation status was divided into moderately or poorly 
differentiated (G2+G3) and well differentiated (G1). Table 2 shows the correlation 
between the Prx I expression and the clinical features for each case. The analysis 
showed that Prx I-positive groups included significantly more local recurrence cases (P 
= 0.033). No significant difference in Prx I expression was observed with respect to the 
other factors, such as age, sex, T-category, N-category, stage, tumor morphology, or 
lymph node recurrence. We next focused on local recurrence and lymph node recurrence, 
and evaluated whether the Prx I expression could be a useful predictor of recurrence. In 
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considering cervical lymph node recurrence, we included cases that had been treated 
with neck irradiation (those that received linac irradiation) and those that had not, which 
included the remaining cases, treated with interstitial therapy, no irradiation, etc.), and 
treatment with or without neck dissection, as variables to exclude the influence of 
irradiation and neck dissection. By univariate analysis, no significant differences were 
found in association with local recurrence and clinical features (age, sex, TNM 
classification, differentiation) except Prx I expression. There was no significant 
difference for lymph node recurrence associated with clinical features including neck 
dissection, irradiation, and Prx I expression (Tables 3, 4). 
Multivariate analysis of recurrence 
Multivariate analysis was used next, to provide adjusted odds ratios for local and 
lymph node recurrence. The predictor variables for all 132 cases were used in a logistic 
regression model with local recurrence and lymph node recurrence as the dependant 
variables. A logistic model for predicting the local or lymph node recurrence was 
constructed using clinical variables, including age, sex, T- and N-category, stage, 
differentiation, tumor morphology, and Prx I expression. For simplicity, the tumor 
morphology classification was divided into two groups (endophytic or other). For our 
analysis of lymph node recurrence, we entered the use of neck irradiation and the use of 
neck dissection as forced variables to exclude the influence of therapeutic differences. 
The adjusted odds ratios (OR) and 95% confidence intervals (CI) for local recurrence 
and lymph node recurrence are shown in Tables 5 and 6. Prx I expression (OR = 2.84; 
95% confidence interval: 1.09-7.43; P = 0.034) was significantly associated with local 
 YANAGAWA-9 
recurrence, but the other predictors were not. The analysis of lymph node recurrence 
showed that Prx I expression (OR = 2.86; 95% confidence interval: 1.02-8.01; P = 
0.046) and differentiation (OR = 3.77; 95% CI: 1.32-10.78; P = 0.013) were 
significantly associated, but the other predictors were not. 
 
 
 Discussion 
In this study we found Prx I expression to be significantly associated with local 
recurrence (P = 0.033) by univariate analysis, and both local (OR = 2.84; 95% 
confidence interval: 1.09-7.43; P = 0.034) and lymph node (OR = 2.86; 95% confidence 
interval: 1.02-8.01; P = 0.046) recurrence by multivariate analysis. These results 
indicate that Prx I expression predicts a 2.8-2.9-fold more frequent incidence of local 
and lymph node recurrence.  
   We can hypothesize why the Prx I-expressing tumors tended to recur. One 
explanation is that tumor recurrence may be ascribed to tumor viability. Prx I was 
originally isolated from proliferating cells13 and Prx I overexpression has been reported 
in some tumors6, 11. These studies show that highly proliferative cells, like tumor cells, 
express more Prx I than do normal cells. Furthermore, among thyroid tumors, the more 
proliferative types of tumors tend to express more Prx I25. Taken together, these results 
support the association between Prx I and tumor viability.  
Another explanation involves Prx I’s ability to act as a tumor suppressor through 
the reduction of ROS. ROS and the reactive oxygen metabolites (ROM) that are formed 
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in the process of cellular respiration are implicated in tumor formation and promotion. 
By causing DNA damage, ROM are thought to affect protooncogenes and tumor 
suppressor genes16. Previous reports show that over-expression of Pag, human Prx I, 
counteracts the physiological role of the protooncogene abl, which has a cytostatic 
effect on cells. Elevated levels of Prx I in tumor cells seem to abrogate the abl-induced 
cell-cycle block14, 23. Recently, studies using a Prx I-knockout mouse indicated that Prx I 
expression was associated with oxidative damage and the presence of malignant 
neoplasms10. These findings indicated that in normal cells Prx I plays a direct role in 
tumor suppression by eliminating ROS and preventing oxidative damage10. Similarly, 
excessively proliferative tumor cells may express Prx I to protect themselves from 
oxidative damage.  
The radiosensitivity of tumors may also be related to their recurrence through a 
mechanism involving Prx I. Many patients in this report were treated with radiotherapy. 
Irradiation can induce Prx I expression, which protects cells from further radiation 
damage2. However, these results suggest that protection by Prx I may also play an 
important role in the survival of cancer cells in patients undergoing radiation therapy, 
and therefore the residual carcinoma may easily recur. 
    We previously reported the potential of using Prx I as a marker for 
clinicopathological features26. In that report, we determined Prx I expression in oral 
SCC in various regions by immunohistochemistry and found an association between Prx 
I expression and T and N classification. In the present report, we used a uniform sample 
type from only the tongue, and the measure of Prx I expression was changed to 
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“negative or positive staining”, because the punch biopsy samples were very small and 
the determination of expression level was difficult. Furthermore, therapeutic and 
diagnostic methods were different between the different institutions. Thus Prx I-positive 
cases in the present report include more cases of smaller mass, but there was no 
significant difference in the results. Note, however, that Prx I expression may be 
associated with proliferative factors, because both T category and recurrence are 
dependant on the viability of the tumor. 
There are many markers that indicate cell proliferation: AgNORs, PCNA, Ki 67, 
and others are well known and have been investigated as prognostic markers for cancers 
of the head and neck region7, 20-22. In this study we found a correlation between Prx I 
and local and lymph node recurrence, but not with prognosis (data not shown). However, 
most markers do not relate to the oxidative responses in cells. The Prx I indicates not 
only proliferation, but also the level of protection against oxidative damage. Therefore, 
it may provide a novel index with which to characterize tumors. 
In this report, we have shown that Prx I may be useful as a tumor recurrence 
marker, which could be beneficial if applied clinically. For example, we could use it to 
estimate whether a tumor is susceptible to recurrence, and apply this information by 
making a wider area of excision or additional treatment, such as chemotherapy for 
positive tumors, to prevent recurrence. Further study is necessary to develop methods to 
apply Prx I as a marker for a more precise assessment of tongue SCC recurrence. 
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Figure legends 
 
Figure 1. Representative photomicrographs of immunochemical staining with anti-Prx I 
antibodies. Negative staining (a total absence of Prx I immunostaining) (A), positive 
staining (B) (original magnification, x100). 
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n
Median age 60
Range 27-88
Sex ratio f/m 45/ 87
Tumor morpholo Superficial 24
Exophytic 22
Endophytic 58
Combined 28
TNM classification
T category T1 37
T2 55
T3 30
T4 10
N category N0  90
N1 18
N2a 4
N2b 13
N2c 6
N3 1
M category M0 131
M1 1
Stage  I 37
 II 40
 III 27
IV 28
Differentiation
G1 80
G2 47
G3 5
G4 0
Total 132
Table 1 . Characteristics of tongue squamous cell ca
Table1
Negative Positive P value
Age
60> 24 41 0.46
≧60 29 38
Sex
f 19 26 0.73
m 34 53
Tumor morphology
Superficial 10 14 0.28
Exophytic 5 17
Endophytic 27 31
Combined 11 17
T category
T1+2 34 58 0.25
T3+4 19 21
N category
N0 36 54 0.95
N1+2 17 25
Stage
I+II 31 46 0.98
III+IV 22 33
Differentiation
G1 33 47 0.74
G2+3 20 32
Local recurrence
recurrence 7 23 0.033
null 46 56
Lymph node recurrence
recurrence 16 14 0.094
null 53 79
Table 2.  Correlation with Peroxiredoxin I expression
and clinical features
Table 2
recurrence null P
Age 60> 17 48 0.35
≧60 13 54
Sex f 9 36 0.59
m 21 66
T category T1+2 21 71 0.97
T3+4 9 31
N category N0 21 69 0.81
N1+2 9 33
Stage I+II 19 58 0.53
III+IV 11 44
Differentiation G1 17 63 0.62
G2+3 13 39
Tumor morpholoSuperficial 7 17 0.72
Exophytic 6 16
Endophytic 11 47
Combined 6 22
Prx I expression Negative 7 46 0.033
Positive 23 56
Table 3.  Univariate analysis of local recurrence
Table3
recurrence null P
Age 60> 12 53 0.25
≧60 18 49
Sex f 10 35 0.92
m 20 67
T category T1+2 19 73 0.39
T3+4 11 29
N category N0 17 73 0.12
N1+2 13 29
Stage I+II 14 63 0.14
III+IV 16 39
Differentiation G1 14 66 0.075
G2+3 16 36
Tumor morpholog Superficial 3 21 0.37
Exophytic 4 18
Endophytic 17 41
Combined 6 22
Neck dissection none 22 71 0.69
performed 8 31
Neck irradiation none 5 22 0.56
performed 25 80
Prx I expression Negative 16 53 0.094
Positive 14 79
Table 4.  Univariate analysis of lymph node recurrence
Table4
j
odds
ratio 95% CI P value
Age (60>:60≦) 0.84 0.34-2.04 0.69
Sex (f:m) 1.32 0.51-3.38 0.57
T category (T1+2:T3+4) 3.90 0.60-25.46 0.16
N category (N0:N1+2) 2.10 0.34-13.09 0.72
Stage ( I+II:III+IV) 0.18 0.15-2.08 0.17
Differentiation (G2+3:G1) 0.82 0.34-1.98 0.66
Tumor morphology (endophytic:the others) 1.59 0.56-4.47 0.38
Prx I expression (negative:positi 2.84 1.09-7.43 0.034
Table 5.  Multivariate analysis of local recurrence
Table5
j
d odds
ratio 95% CI P value
Age (60>:60≦) 0.38 0.13-1.11 0.08
Sex (f:m) 1.12 0.37-3.34 0.84
T category (T1+2:T3+4) 5.30 0.87-32.41 0.07
N category (N0:N1+2) 0.40 0.51-3.11 0.38
Stage ( I+II:III+IV) 0.25 0.02-3.34 0.29
Differntiation (G2+3:G1) 3.77 1.32-10.78 0.013
Tumor morphology (endophytic:the others) 1.33 0.40-4.40 0.46
Neck dissection (none:perform 3.92 0.92-0.16.59 0.63
Neck irradiation  (none:perform 0.90 0.21-3.83 0.88
Prx I expression (negative:posi 2.86 1.02-8.01 0.046
Table 6.  Multivariate analysis of lymph node recurrence
Table6

